| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.06▲ | 1.06▲ | 1.06▲ | 1.08▲ | 1.05▲ |
| MA10 | 1.04▲ | 1.05▲ | 1.05▲ | 1.05▲ | 1.16▼ |
| MA20 | 1.04▲ | 1.05▲ | 1.04▲ | 1.06▲ | 1.31▼ |
| MA50 | 1.04▲ | 1.08▲ | 1.10▼ | 1.21▼ | 1.81▼ |
| MA100 | 1.11▼ | 1.16▼ | 1.19▼ | 1.36▼ | 1.97▼ |
| MA200 | 1.19▼ | 1.28▼ | 1.31▼ | 1.73▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.007▲ | 0.009▲ | 0.011▲ | 0.017▲ | -0.006▼ |
| RSI | 69.976▲ | 60.413▲ | 56.629▲ | 47.274▼ | 36.455▼ |
| STOCH | 47.778 | 42.222 | 46.389 | 68.628 | 13.856▼ |
| WILL %R | -13.333▲ | -13.333▲ | -11.765▲ | -30.000 | -80.000▼ |
| CCI | 205.702▲ | 171.569▲ | 165.855▲ | 100.648▲ | -70.893 |
|
Wednesday, October 14, 2026 01:18 PM
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® ...
|
|
Thursday, September 03, 2026 07:54 AM
ImmunityBio looks attractive due to ANKTIVA's FDA approval for BCG-unresponsive NMIBC and pipeline expansion potential. See why I rate IBRX stock a Buy.
|
|
Friday, August 14, 2026 04:29 AM
As a reminder, CG Oncology, Inc. is a Dallas, Texas-based late-clinical-stage biopharmaceutical concern focused on the development of cretositimogene grenadenorepvec (hereafter “cret”) for the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/10/26 | 1.09 | 1.09 | 1.09 | 1.09 | 2,706 |
| 23/10/26 | 1.0923 | 1.15 | 1.0415 | 1.065 | 5,838 |
| 22/10/26 | 1.12 | 1.12 | 1.07 | 1.09 | 5,729 |
| 21/10/26 | 1.12 | 1.13 | 1.08 | 1.08 | 10,966 |
| 20/10/26 | 1.03 | 1.08 | 1.03 | 1.08 | 3,248 |
| 19/10/26 | 1.02 | 1.065 | 1.02 | 1.04 | 39,689 |
| 16/10/26 | 1.0301 | 1.0301 | 1.02 | 1.02 | 5,409 |
| 15/10/26 | 1.015 | 1.035 | 1.015 | 1.03 | 4,503 |
| 14/10/26 | 1.00 | 1.02 | 0.9977 | 1.00 | 26,811 |
| 13/10/26 | 1.01 | 1.04 | 0.9999 | 1.02 | 10,157 |
|
|
||||
|
|
||||
|
|